Severe and Refractory gastroparesis can be treated with endoscopic pyloromyotomy: BMJ
A recent study finds endoscopic pyloromyotomy (G-POEM), a minimally invasive treatment option for patients with gastroparesis, improves the symptoms and also gastric emptying 6 months post procedure. The findings were published in British Medical Journal - Gut.
This prospective randomized trial compared G-POEM with sham in patients with severe gastroparesis. The primary outcome was the proportion of patients with treatment success (defined as a reduction of at least 50% in the Gastroparesis Cardinal Symptom Index (GCSI) at 6 months). Patients were randomized to the sham group with persistent symptoms and offered crossover G-POEM. Enrollment was suspended after an interim analysis by the Information and Security Control Authority prior to the planned sample of 86 patients.
The key highlights of the study were:
A total of 41 patients (17 diabetic, 13 postoperative, 11 idiopathic; 6% male) were randomized into G-POEM and sham groups (21:20).
The treatment success rates were 71% (95% CI 50-86) after G-POEM and 22% (8-47) after sham (p = 0.005).
Treatment success rates in patients with diabetic, postoperative and idiopathic gastroparesis were 89% (95% CI 56–98), 50% (18 - 82) and 67% (30 - 90) after G-POEM; In the sham group, the corresponding figures were 17% (3-57), 29% (7-67) and 20% (3-67).
Mean gastric retention at 4 hours decreased from 22% (95% CI 17-31) to 12% (5-22) after G-POEM and was unchanged after sham: 26% (18-39) vs. 24% (11–35).
12 patients underwent G-POEM treatment, of which 9 (75%) were successful.
G-POEM for severe gastroparesis was superior to sham procedures in improving both symptoms and gastric emptying 6 months after the procedure according to the extensive findings of this study.
Source:
Martinek, J., Hustak, R., Mares, J., Vackova, Z., Spicak, J., Kieslichova, E., Buncova, M., Pohl, D., Amin, S., & Tack, J. (2022). Endoscopic pyloromyotomy for the treatment of severe and refractory gastroparesis: a pilot, randomised, sham-controlled trial. Gut, 71(11), 2170–2178. https://doi.org/10.1136/gutjnl-2022-326904
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.